查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1639226

疫苗佐剂市场机会、成长动力、产业趋势分析与预测 2025 - 2034

Vaccine Adjuvants Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024年，全球疫苗佐剂市场达到13亿美元，预计2025年至2034年复合年增长率为6.5%。透过增强免疫反应，佐剂提高了疫苗的有效性，确保更强、更持久的保护。它们还允许使用较少的抗原，使疫苗更具成本效益，同时提高其整体效率。

市场按产品类型分类，包括皂苷类佐剂、乳液佐剂、病原体成分、颗粒佐剂等。其中，颗粒助剂在2024年引领市场，占营收的35.4%。全球传染病流行率不断上升，加大了对高效疫苗的需求。颗粒佐剂对于改善免疫反应至关重要，使其成为疫苗开发的关键要素。它们在增强免疫活性方面的有效性对于解决广泛的健康问题至关重要，这突显了它们在疫苗配方中日益增长的重要性。

另一个重要的市场区隔是基于给药途径，包括肌肉内、皮下、口服和其他方法。肌肉注射途径在 2024 年占据市场主导地位，占据 59.3% 的份额，预计将继续保持上升趋势，到 2034 年将达到 14 亿美元。对于传染病高危险群尤其重要。对有效疫苗的需求不断增加，特别是在全球健康挑战之后，进一步强调了肌内佐剂给药的重要性。这种方法增强了疫苗的性能，并在全球疫苗接种活动中发挥关键作用。

市场范围
开始年份 2024年
预测年份 2025-2034
起始值 13亿美元
预测值 23亿美元
复合年增长率 6.5%

美国疫苗佐剂市场预计将大幅成长，到 2034 年将达到 9.275 亿美元。此外，製药公司、学术机构和研究组织之间的合作正在推动该领域的创新，为新的和改进的佐剂技术铺平道路，这些技术将在增强未来疫苗配方方面发挥关键作用。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 对有效和持久免疫的需求不断增加
      • 传染病和流行病日益流行
      • 增加政府和私人资金用于疫苗开发
    • 产业陷阱与挑战
      • 成本高、开发週期长
      • 严格的监管要求
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 未来市场趋势
  • 管道分析
  • 差距分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品类型，2021 - 2034 年

  • 主要趋势
  • 佐剂乳剂
  • 病原体成分
  • 皂苷类佐剂
  • 颗粒佐剂
  • 其他产品类型

第 6 章：市场估计与预测：按管理途径，2021 - 2034 年

  • 主要趋势
  • 肌肉注射
  • 皮下
  • 口服
  • 其他给药途径

第 7 章：市场估计与预测：按疾病类型，2021 - 2034 年

  • 主要趋势
  • 传染病
  • 癌症
  • 其他疾病

第 8 章：市场估计与预测：按应用分类，2021 - 2034 年

  • 主要趋势
  • 人类疫苗
  • 兽用疫苗

第 9 章：市场估计与预测：按地区划分，2021 - 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Agenus
  • Allergy Therapeutics
  • Aurorium
  • Brenntag Biosector
  • Croda International
  • CSL Limited
  • Dynavax Technologies Corporation
  • EuBiologics
  • GSK plc
  • Merck KGaA
  • Novavax
  • OZ Biosciences
  • Riboxx GmbH
  • Seppic
  • SPI Pharma
简介目录
Product Code: 12365

The Global Vaccine Adjuvants Market reached USD 1.3 billion in 2024 and is projected to expand at a CAGR of 6.5% from 2025 to 2034. Vaccine adjuvants are added to vaccines to amplify the immune system's response to the antigen. By enhancing immune responses, adjuvants increase the effectiveness of vaccines, ensuring stronger and longer-lasting protection. They also allow for the use of smaller amounts of the antigen, making vaccines more cost-effective while improving their overall efficiency.

The market is categorized by product types, which include saponin-based adjuvants, adjuvant emulsions, pathogen components, particulate adjuvants, and others. Among these, particulate adjuvants led the market in 2024, accounting for 35.4% of revenue. The rising prevalence of infectious diseases globally has intensified the demand for vaccines with higher efficacy. Particulate adjuvants are crucial in improving immune responses, making them a key element in vaccine development. Their effectiveness in boosting immune activity is vital for tackling widespread health concerns, underlining their growing importance in vaccine formulations.

Another significant market segmentation is based on the route of administration, including intramuscular, subcutaneous, oral, and other methods. The intramuscular route dominated the market in 2024, holding a 59.3% share, and is expected to continue its upward trajectory, reaching USD 1.4 billion by 2034. Vaccines administered intramuscularly with adjuvants have proven to trigger strong and long-lasting immune responses, which are particularly important for populations at higher risk of infectious diseases. The increased demand for effective vaccines, particularly following global health challenges, has further emphasized the importance of intramuscular adjuvant administration. This method enhances vaccine performance and plays a critical role in vaccination campaigns worldwide.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.3 Billion
Forecast Value$2.3 Billion
CAGR6.5%

U.S. vaccine adjuvants market is anticipated to see substantial growth, reaching USD 927.5 million by 2034. Key U.S. government agencies invest in vaccine research, focusing on improving adjuvants to boost vaccine efficacy against a wide range of diseases. Moreover, collaborative efforts between pharmaceutical companies, academic institutions, and research organizations are driving innovation in the field, paving the way for new and improved adjuvant technologies that will play a pivotal role in enhancing future vaccine formulations.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing demand for effective and long-lasting immunity
      • 3.2.1.2 Growing prevalence of infectious diseases and pandemics
      • 3.2.1.3 Increased government and private funding for vaccine development
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High costs and lengthy development timelines
      • 3.2.2.2 Stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Pipeline analysis
  • 3.8 Gap analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Adjuvant emulsions
  • 5.3 Pathogen components
  • 5.4 Saponin-based adjuvants
  • 5.5 Particulate adjuvants
  • 5.6 Other product types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Intramuscular
  • 6.3 Subcutaneous
  • 6.4 Oral
  • 6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Infectious diseases
  • 7.3 Cancer
  • 7.4 Other diseases

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Human vaccines
  • 8.3 Veterinary vaccines

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Agenus
  • 10.2 Allergy Therapeutics
  • 10.3 Aurorium
  • 10.4 Brenntag Biosector
  • 10.5 Croda International
  • 10.6 CSL Limited
  • 10.7 Dynavax Technologies Corporation
  • 10.8 EuBiologics
  • 10.9 GSK plc
  • 10.10 Merck KGaA
  • 10.11 Novavax
  • 10.12 OZ Biosciences
  • 10.13 Riboxx GmbH
  • 10.14 Seppic
  • 10.15 SPI Pharma